Dr D'Sa is a haematologist with a specialist interest in Waldenström’s macroglobulinaemia and associated disorders, myeloma and POEMS syndrome, working both at University College London Hospitals NHS Foundation Trust, London and the Mount Vernon Cancer Centre, Northwood. She has weekly specialist clinics in Waldenström’s Macroglobulinaemia, Myeloma and Lymphoma and well as monthly Joint Neuropathy/POEMS Clinics with Dr Michael Lunn at the National Hospital for Neurology and Neurosurgery, London. Dr D’Sa has worked with patients and colleagues to set up an not-for-profit organisation called WMUK (www.wmuk.org.uk), which seeks to bring health professionals and patients closer together to challenge the barriers faced by patients with Waldenström’s Macroglobulinaemia, including the organisation of patient seminars for patients from across the UK and beyond. She is a co-author of the recently published UK WM Treatment Guidelines 2014 under the auspices of the British Committee for Standards in Haematology and has recently been awarded a grant by WMUK to set up a WM Biobank and Registry at UCLH which will be linked to the development of the Rory Morrison WMUK online Clinical Registry which will store UK clinical data for Waldenström's macroglobulinaemia and closely associated B-cell malignancies. Dr D’Sa is working with Colleagues in the WMUK Doctors’ Forum to develop a blueprint for clinical trials in the UK, with a view to improving the understanding of the biology of WM as well as access to novel therapeutic agents.
Dr D’Sa has a background in laboratory research into the recovery of immune function following allogeneic stem cell transplantation in myeloma patients.
Currently her research is clinically orientated and comprises clinical trials in the field of Waldenström’s macroglobulinaemia, myeloma and other lymphomas, including Phase I, II and II trials of novel therapies.
With colleagues in WMUK, in particular Dr Helen McCarthy (Bournemouth) she is seeking to capture an accurate picture of Waldenstroms in the UK through national Registry project, as well as developing the WM Biobank at the UCL Cancer Institute as a basis for bench to bedside projects, in collaboration with (inter)national colleagues.